Kanzaki S, Hilliker S, Baylink D J, Mohan S
Department of Medicine, Loma Linda University, California.
Endocrinology. 1994 Jan;134(1):383-92. doi: 10.1210/endo.134.1.7506211.
Previous studies have shown that the actions of insulin-like growth factor-II (IGF-II) in bone are determined by both its concentration and the concentrations of the IGF-binding proteins (IGFBPs). As IGFBP concentrations may be regulated not only at the level of production, but also at the level of degradation, IGFBP proteases may be an important component of the IGF-II regulatory system. In this study, we have identified IGFBP-4 and IGFBP-5 protease activity in the conditioned medium (CM) of the human osteosarcoma U2 cell line (U2OS) and untransformed normal human bone cell (HBC) derived from skull. Proteolysis of the 29-kilodalton (kDa) [125I]IGFBP-5 produced an 18- to 20-kDa fragment of IGFBP-5, and 25 kDa [125I]IGFBP-4 yielded two lower mol wt fragments in the presence of IGF-II. CM from IGF-II-treated U2OS and normal HBC cultures exhibited decreased IGFBP-5 proteolytic activity compared to control cultures. In contrast, CM from IGF-II-treated HBC cultures had increased proteolytic activity against IGFBP-4. To determine the mechanisms by which IGF-II modulates IGFBP-4 and -5 proteolytic activity, CM from control U2OS cell culture was incubated with [125I]IGFBP-4 or -5 in the presence of various concentrations of IGF-II and IGF analogs under cell-free conditions. It was found that exogenous IGF-II stimulated IGFBP-4 proteolysis, but IGF analogs that had no or extremely low affinity to IGFBP-4 failed to induce IGFBP-4 proteolysis. On the contrary, exogenous IGF-II had no effect on IGFBP-5 proteolysis in cell-free U2OS CM. Both IGFBP-4 and IGFBP-5 proteolytic activities were inhibited by aprotinin, zinc chloride, and EDTA and eluted as a single major peak between mol wt markers of 160 and 67 kDa upon gel filtration. Based on the findings that HBCs in culture produce a protease(s) capable of cleaving both IGFBP-4 and IGFBP-5 and that IGF-II can promote or inhibit proteolytic degradation of IGFBP-4 and IGFBP-5, respectively, it is proposed that IGFBP protease(s) may be an important modulator of IGF activity in bone.
先前的研究表明,胰岛素样生长因子-II(IGF-II)在骨骼中的作用取决于其浓度以及IGF结合蛋白(IGFBPs)的浓度。由于IGFBP浓度不仅可能在产生水平受到调节,还可能在降解水平受到调节,因此IGFBP蛋白酶可能是IGF-II调节系统的重要组成部分。在本研究中,我们在人骨肉瘤U2细胞系(U2OS)和源自颅骨的未转化正常人类骨细胞(HBC)的条件培养基(CM)中鉴定出了IGFBP-4和IGFBP-5蛋白酶活性。29千道尔顿(kDa)的[125I]IGFBP-5经蛋白水解产生了一个18至20 kDa的IGFBP-5片段,在IGF-II存在的情况下,25 kDa的[125I]IGFBP-4产生了两个较低分子量的片段。与对照培养物相比,来自IGF-II处理的U2OS和正常HBC培养物的CM显示出降低的IGFBP-5蛋白水解活性。相反,来自IGF-II处理的HBC培养物的CM对IGFBP-4的蛋白水解活性增加。为了确定IGF-II调节IGFBP-4和-5蛋白水解活性的机制,在无细胞条件下,将来自对照U2OS细胞培养物的CM与[125I]IGFBP-4或-5在各种浓度的IGF-II和IGF类似物存在下孵育。发现外源性IGF-II刺激IGFBP-4蛋白水解,但对IGFBP-4无亲和力或亲和力极低的IGF类似物未能诱导IGFBP-4蛋白水解。相反,外源性IGF-II对无细胞U2OS CM中的IGFBP-5蛋白水解没有影响。IGFBP-4和IGFBP-5的蛋白水解活性均受到抑肽酶、氯化锌和EDTA的抑制,并且在凝胶过滤时在分子量标记物160和67 kDa之间作为单一主峰洗脱。基于培养中的HBC产生能够切割IGFBP-4和IGFBP-5的一种或多种蛋白酶以及IGF-II可以分别促进或抑制IGFBP-4和IGFBP-5的蛋白水解降解这一发现,有人提出IGFBP蛋白酶可能是骨骼中IGF活性的重要调节剂。